Download PDF
Thromb Haemost 1972; 27(01): 019-024
DOI: 10.1055/s-0038-1649005
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Immune Reactive Factor IX in Acquired Factor IX Deficiency[*]

K Lechner
1   First Department of Medicine, University of Vienna, Austria (Head: Prof. Dr. E. Deutsch)
› Author Affiliations
Further Information

Publication History

Publication Date:
29 June 2018 (online)

    Permissions and Reprints

Summary

Factor IX-antibody-neutralizing material has been estimated in plasmas of patients with acquired factor IX deficiency. In patients with liver cirrhosis and patients who had been treated with L-Asparaginase the plasma neutralized an amount of antibody expected from the biological activity. In patients treated with phenprocoumon and in one patient with biliary obstruction an excess of factor IX-antibody neutralizing material was found. This inactive factor IX probably represents a precursor molecule of factor IX.

* Supported by a grant of the “Österreichische Fonds zur Förderung der Wissenschaftlichen Forschung” (Nr. 900).


 

  • References

  • 1 Denson K. W. E, Biggs R, Haddon M. E, Borrett R, Cobb K. Two types of haemophilia (A+ and A-): A study of 48 cases. Brit. J. Haemat 17: 163 1969;
    CrossrefPubMedGoogle Scholar
  • 2 Deutsch E, Fischer M, Frischauf H, Honetz N, Lechner K, Pesendorfer F, Stych H, Weissmann A. Blood coagulation changes under L-Asparaginase therapy. In: Recent results in cancer research: Experimental and clinical effects of L-asparaginase. Edited Grundmann E, Oettgen H. F. 331 Springer-Verlag; Berlin - Heidelberg - New York: 1970
    Google Scholar
  • 3 Grundmann E. Grundlagen der L-Asparaginase-Therapie. In: Chemo- und Immunothérapie der Leukosen und malignen Lymphome. Ed. Stacker A. 23 Bohmann, Wien: 1969
    Google Scholar
  • 4 Goodnight S. H, Feinstein D. I, Osterud B, Rapaport S. I. Factor VII antibodyneutralizing material in hereditary and acquired factor VII deficiency. Blood 28: 1 1971;
    PubMedGoogle Scholar
  • 5 Hemher H. G, Veitkamp J. J, Hensen A, Loeliger E. A. Nature of prothrombin biosynthesis: Preprothrombinaemia in vitamin K-deficiency. Nature (Lond) 200: 589 1963;
    CrossrefPubMedGoogle Scholar
  • 6 Hemher H. C, Muller A. D. Kinetic aspects of the interaction of blood clotting enzymes V. The reaction mechanism of the extrinsic coagulation system as revealed by the kinetics of one- stage estimations of coagulation enzymes. Thrombos. Diathes. haemorrh. (Stuttg) 19: 368 1968;
    PubMedGoogle Scholar
  • 7 Hemher H. V, Veitkamp J. J, Loeliger E. A. Kinetic aspects of the interaction of blood enzymes, III. The reaction mechanism of the extrinsic clotting system as revealed by the kinetics of one-stage estimations of coagulation enzymes. Thrombos. Diathes. haemorrh. (Stuttg) 19: 346 1968;
    PubMedGoogle Scholar
  • 8 Hemher H. G, Muller A. D, Loeliger E. A. Preliminary reports: Two types of prothrombin in vitamin K-deficiency. Thrombos. Diathes. haemorrh. (Stuttg) 23: 633 1970;
    PubMedGoogle Scholar
  • 9 Hoyer L. W, Breckenridge R. T. Immunologic studies of anti-hemophilic factor (AHF, factor VIII): Cross-reacting material in a genetic variant of hemophilia A. Blood 32: 962 1968;
    PubMedGoogle Scholar
  • 10 Josso F, Lavergne J. M, Gouault M, Prou-Wartelle O, Soulier J. P. Différents états moléculaires du facteur II (prothrombine). Leur étude à l’aide de la staphylocoagulase et d’anticorps anti-facteur II. I. Le facteur II chez les sujets traités par les antagonistes de la vitamine K. Thrombos. Diathes. haemorrh. (Stuttg) 20: 88 1968;
    PubMedGoogle Scholar
  • 11 Larrieu M. J, Meyer D. Abnormal factor IX during anticoagulant treatment. Lancet 02: 1085 1970;
    PubMedGoogle Scholar
  • 12 Lechner K. Factor IX-inhibitors. Report of two cases and a study of the biological, chemical and immunological properties of the inhibitors. Thrombos. Diathes. haemorrh. (Stuttg) 25: 447 1971;
    PubMedGoogle Scholar
  • 13 Meyer D, Dreyfus M, Larrieu M. J. Inactive factor IX during anticoagulant treatment. Second conference thrombosis and haemostasis; Oslo: 1971
    Google Scholar
  • 14 Prentice G. M. Panel discussion. The International Society on Thrombosis and Haemostasis; Montreux, Switzerland: Juli 29 - August 1, 1970
    Google Scholar
  • 15 Prydz H. The mode of action of peroral anticoagulants. Abstr. XIII Internat. Congr. Hematol., Munich. 1970: 70.
    PubMedGoogle Scholar
  • 16 Prydz H, Gladhaug A. Factor X. Immunological Studies. Thrombos. Diathes. haemorrh. (Stuttg) 25: 157 1971;
    PubMedGoogle Scholar
  • 17 Roberts H. R, Grizzle J. E, McLester W. D. et al. Genetic variants of hemophilia B: detection by means of a specific PTC inhibitor. J. clin. Invest 47: 360-365. 1968;
    CrossrefPubMedGoogle Scholar
  • 18 Veltkamp J. J, Muis H, Muller A. D, Hemker H. G, Loeliger E. A. Additional evidence for the existence of a precursor molecule of the prothrombin complex in oral anticoagulation. Thrombos. Diathes. haemorrh. (Stuttg) 25: 312 1971;
    PubMedGoogle Scholar
  • 19 Zimmerman T. S, Ratnojf O. D, Powell A. E. The immunologic differentiation of the antihemophilic factor (factor VIII) abnormalities in classic hemophilia and von Willebrand’s disease. J. clin. Invest 49: 106a 1970;
    CrossrefPubMedGoogle Scholar